These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24847087)

  • 1. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
    Gozé C; Blonski M; Le Maistre G; Bauchet L; Dezamis E; Page P; Varlet P; Capelle L; Devaux B; Taillandier L; Duffau H; Pallud J
    Neuro Oncol; 2014 Aug; 16(8):1100-9. PubMed ID: 24847087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.
    Pallud J; Blonski M; Mandonnet E; Audureau E; Fontaine D; Sanai N; Bauchet L; Peruzzi P; Frénay M; Colin P; Guillevin R; Bernier V; Baron MH; Guyotat J; Duffau H; Taillandier L; Capelle L
    Neuro Oncol; 2013 May; 15(5):595-606. PubMed ID: 23393207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
    Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
    Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
    Wang YY; Wang K; Li SW; Wang JF; Ma J; Jiang T; Dai JP
    AJNR Am J Neuroradiol; 2015 Nov; 36(11):2023-9. PubMed ID: 26316565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
    Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
    J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.
    Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H
    Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
    Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
    Int J Clin Exp Pathol; 2013; 6(1):31-40. PubMed ID: 23236540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
    Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
    Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
    J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
    Neal A; Kwan P; O'Brien TJ; Buckland ME; Gonzales M; Morokoff A
    Epilepsy Behav; 2018 Jan; 78():30-36. PubMed ID: 29172136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas.
    Gozé C; Mansour L; Rigau V; Duffau H
    J Neurosurg; 2013 Apr; 118(4):866-72. PubMed ID: 23330999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.